- LECTURER Oncological Sciences
Dr. Erblich's research focuses on the interactions among emotional, cognitive, behavioral and genetic factors in cancer prevention and control. Current efforts focus on three areas: nicotine dependence, alcoholism, and familial breast cancer risk. In studying nicotine dependence, Dr. Erblich's research takes a multidisciplinary-translational approach, with hypotheses driven by both the human and animal literatures that have contributed to the current understanding of motivations for drug use. The overall goal of Dr. Erblich's research in this area is to better understand how cognitive-behavioral and genetic factors impact smoking behavior. Projects in this area include studies of the effects of dopamine-related genetic polymorphisms on smokers cigarette cravings induced by laboratory stressors, conditioned cues/triggers, and other manipulations. Also studied are effects of family history, cognitive factors, and personality factors on smoking behavior, as well as effects of alcoholism and polysubstance abuse. The research thus draws upon behavioral principles, such as personality, conditioning, and stress reactivity, as well as molecular biological principles, including genetic and cellular mechanisms of dopamine transmission. It is anticipated that the research program will lead to effective multifaceted treatments for tobacco smoking, which continues to contribute unabatedly to the cancer burden at alarming rates.
Dr. Erblich's lab is also involved in examining the psychological and behavioral consequences of familial risk for breast cancer. While 1 in 8 women in the general population develop this disease, rates are markedly higher among women with positive family histories, and even higher among women found to be carriers of several known genetic mutations. The potential for high levels of psychological distress attendant to this level of risk is a focus of the lab's work. In addition, Dr. Erblich's lab is investigating the possibility that stress in women at risk for breast cancer may impact women's ability to process complex information provided during clinical interactions, possibly rendering them less likely to make informed decision about their health care. As above, the research is multidisciplinary in nature, bringing together psychological and biological principles, including distress, cognitive processing, stress-reactivity, and genetics. Thus, the goal of this line of research is not only to better understand the full impact of risk for breast cancer on women's psychological functioning and decision making, but also to explore potential psychological and behavioral mechanisms that may contribute to disease burden in this population.
Tong C, Bovbjerg DH, Erblich J. Smoking-related videos for use in cue-induced craving paradigms. Addict Behav 2007 Dec; 32(12): 3034-3044.
Colamussi L, Bovbjerg DH, Erblich J. Stress- and cue-induced cigarette craving: effects of a family history of smoking. Drug Alcohol Depend. 2007 May; 88(2-3): 251-258.
Erblich J, Earleywine M. Alcohol Problems: Causes, Definitions, and Treatments. In: Cohen L, McChargue D, Collins F, editors. The Health Psychology Handbook: Practical Issues for the Behavioral Medicine Specialist. Newbury Park, CA, Sage Publications; 2003.
Erblich J, Earleywine M, Erblich B. Biphasic stimulant and sedative effects of ethanol: are children of alcoholics really different?. Addict Behav 2003 Aug; 28(6): 1129-39.
Erblich J, Boyarsky Y, Spring B, Niaura R, Bovbjerg DH. A family history of smoking predicts heightened levels of stress-induced cigarette craving. Addiction 2003 May; 98: 657-64.
Erblich J, Earleywine M. Behavioral undercontrol and subjective stimulant and sedative effects of alcohol intoxication: independent predictors of drinking habits?. Alcohol Clin Exp Res 2003 Jan; 27(1): 44-50.
Erblich J, Bovbjerg DH. In vivo versus imaginal smoking cue exposures: is seeing believing?. Exp Clin Psychopharmacol 2004 Aug; 12(3): 208-15.
Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH. Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms. Pharmacogenomics J 2004; 4(2): 102-9.
Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH. Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers. Mol Psychiatry 2005 Apr; 10(4): 407-14.
Erblich J, Brown K, Kim Y, Valdimarsdottir HB, Livingston BE, Bovbjerg DH. Development and validation of a Breast Cancer Genetic Counseling Knowledge Questionnaire. Patient Educ Couns 2005 Feb; 56(2): 182-91.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Erblich did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 2nd Fl Room Room 2-70
1425 Madison Avenue
New York, NY 10029